Recent Company News

• 07:06 AM ET Jul 21, 2025
  

  Ionis Pharmaceuticals announces journal publication of data from Phase 3 OASISplus prospective switch study of donidalorsen in patients with HAE ($41.76, 0.00)

• 05:48 PM ET Jul 18, 2025
  

  Otsuka and Lundbeck issue statement on FDA advisory committee meeting results for sNDA of Rexulti in combo with setraline for PTSD (DKK 33.86, 0.00)

• 03:41 PM ET Jul 18, 2025
  

  FDA panel votes against the efficacy data of Rexulti in combo with setraline for PTSD (¥6581.0000, 0)

• 08:58 AM ET Jul 16, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:24 PM ET Jul 15, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:20 AM ET Jul 16, 2025
  

  FDA releases briefing materials ahead of Friday's Adcom for Rexulti in PTSD (¥6587.0000, 0)